Summary

• INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of cerebrovascular adverse reactions and death. INVEGA TRINZA is not approved for use in patients with dementia-related psychosis.¹
• Clinical studies of INVEGA TRINZA did not include sufficient numbers of patients ≥65 to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.²
• No dose adjustments are needed for elderly patients with normal renal function. However, there may be age-related decreases in creatinine clearance.³
• This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment, who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, monitor renal function and adjust dosage.^1,3
• For patients with mild renal impairment (creatinine clearance ≥50 mL/min to <80 mL/min [Cockcroft-Gault Formula]), initiate paliperidone palmitate 1-month at a lower dose, then transition to INVEGA TRINZA.³
• INVEGA TRINZA is not recommended in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min).³

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 17 January 2025.